CVKD
NASDAQCadrenal Therapeutics Inc.
News · 26 weeks57-22%
2026-03-012026-08-23
Mix3690d
- SEC Filings17(47%)
- Insider10(28%)
- Other8(22%)
- Dividends1(3%)
Latest news
25 items- SECSEC Form 10-Q filed by Cadrenal Therapeutics Inc.10-Q - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- SECCadrenal Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- PRCadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering ProcessPONTE VEDRA, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update on the launch of a structured strategic partnering process following significant clinical, regulatory, and portfolio progress across its Cardiac Acute Critical Care Franchise. "The second quarter and subsequent weeks marked an important milestone for Cadrenal," said Quang X. Pham, Chairman and Chief Executive Officer of Cadrenal Therapeutics. "Our obje
- SECSEC Form SCHEDULE 13G filed by Cadrenal Therapeutics Inc.SCHEDULE 13G - Cadrenal Therapeutics, Inc. (0001937993) (Subject)
- SECSEC Form DEFA14A filed by Cadrenal Therapeutics Inc.DEFA14A - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- SECSEC Form DEF 14A filed by Cadrenal Therapeutics Inc.DEF 14A - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- PRCadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 DiscontinuationUrgent Need for Novel Targets - Recent clinical failure of a competing mechanism highlights urgent need for novel upstream targets, such as 12-LOX, that are being studied to address the root causes of cardio-renal injuryDual-Indication Development and Commercialization Strategy Expands the Clinical Advancement of CAD-1005 to target both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI)Addresses High-Value Gap in the Acute Care Market –First-in-class positioning in the $1 billion+ U.S. CSA-AKI market following the recent discontinuation of a competitor's late-stage Phase 3 clinical trial for lack of efficacyGlobal Partnering Potential – Levera
- SECSEC Form PRE 14A filed by Cadrenal Therapeutics Inc.PRE 14A - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- SECCadrenal Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- PRCadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data PresentationCapital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditionsCompany is exploring development, licensing, and commercialization partnerships for CAD-1005, frunexian, and tecarfarinRecently presented Phase 2 CAD-1005 data demonstrated a >25% absolute reduction in thrombotic events in patients with heparin-induced thrombocytopenia PONTE VEDRA, Fla., July 21, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today announced a comprehensive alignment of
- SECSEC Form EFFECT filed by Cadrenal Therapeutics Inc.EFFECT - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- SECSEC Form 424B3 filed by Cadrenal Therapeutics Inc.424B3 - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- SECCadrenal Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- SECSEC Form D filed by Cadrenal Therapeutics Inc.D - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- SECSEC Form S-3 filed by Cadrenal Therapeutics Inc.S-3 - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- SECCadrenal Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- INSIDERChairman and CEO Pham Quang X sold $22,422 worth of shares (7,400 units at $3.03) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 98,589 units (SEC Form 4)4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)
- SECCadrenal Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- PRCadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules$3 million upfront with up to approximately $5.8 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter of 2027; if warrants are exercised in full for cash, it is anticipated that the cash runway would extend into second half of 2027 to advance partnering opportunities for tecarfarin in Kawasaki Disease (potential rare pediatric disease designation) and CAD-1005 in CSA-AKI and HIT PONTE VEDRA, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) (the "Company"), a biopharmaceutical company advancing late-stage novel therapies for life-threatening immune and thrombo
- SECCadrenal Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- INSIDERChairman, CEO and Interim CFO Pham Quang X sold $33,919 worth of shares (11,156 units at $3.04) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 105,989 units (SEC Form 4)4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)
- INSIDERChairman, CEO and Interim CFO Pham Quang X sold $39,829 worth of shares (11,444 units at $3.48) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 117,145 units (SEC Form 4)4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)
- PRCadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 CongressSelection highlights the clinical value potential of Cadrenal’s first-in-class 12-lipoxygenase inhibitor for Heparin-Induced Thrombocytopenia (HIT) First-ever randomized, blinded, placebo-controlled trial in HIT, a life-threatening blood-clotting disorder triggered by an immune reaction to heparin, the most widely used blood thinner in hospitals Phase-3 ready and addresses a peak $2 billion annual revenue potential in the HIT market PONTE VEDRA, Fla., June 24, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company advancing late-stage novel therapies for life-threatening immune and thrombotic conditions, today announced that late-breaking clinica
- INSIDERChairman, CEO and Interim CFO Pham Quang X sold $13,110 worth of shares (4,126 units at $3.18) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 128,589 units (SEC Form 4)4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)
- SECCadrenal Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
CVKD FAQ
6 questionsWhere does CVKD stock trade?
Cadrenal Therapeutics Inc. (CVKD) is listed on NASDAQ.What sector and industry is CVKD in?
Cadrenal Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Cadrenal Therapeutics Inc. go public?
Cadrenal Therapeutics Inc. (CVKD) completed its IPO in 2023.What are analysts saying about CVKD?
Cadrenal Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from Noble Capital Markets: Outperform with a $400.00 price target on 2023-12-18. Recent price targets cluster around $400.00.What companies are similar to CVKD?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CVKD side-by-side with any of them on Quantisnow.How can I track CVKD on Quantisnow?
Quantisnow aggregates Cadrenal Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CVKD to receive live email and push alerts on every new disclosure.